Introduction
============

Liver cancer is the sixth-leading cause of cancer and the second-leading cause of cancer-associated mortality worldwide ([@b1-ol-0-0-7131]), leading to 746,000 mortalities in 2012 ([@b1-ol-0-0-7131]). Hepatoblastoma, an embryonal malignancy originated in hepatocytes, is the most common primary liver tumor in children, and is usually diagnosed in the first 3 years of life ([@b2-ol-0-0-7131]). The incidence of hepatoblastoma in children has gradually increased, and the overall 5-year survival rate in children is \~70% ([@b3-ol-0-0-7131],[@b4-ol-0-0-7131]). The most common manifestation of hepatoblastoma is abdominal distension or presence of a mass ([@b2-ol-0-0-7131]). Hepatoblastoma can generally be cured via tumor resection if the tumor is single, smaller and non-metastasic, but a number of children cannot be cured due to a late diagnosis, multiple subtypes and metastases, which cause a poor prognosis ([@b5-ol-0-0-7131]). Therefore, it is necessary to investigate the molecular mechanisms of hepatoblastoma and lay the basis for refining the current diagnosis or treatment interventions. The HepG2 cell line is originated from hepatoblastoma ([@b6-ol-0-0-7131]); thus, HepG2 cells were selected in the present study to investigate the molecular mechanisms of hepatoblastoma.

MicroRNAs (miRNAs/miRs) are small non-coding RNA molecules involved in diverse cell activities, including regulation of cell proliferation, differentiation, apoptosis and carcinogenesis ([@b5-ol-0-0-7131],[@b6-ol-0-0-7131]). miR-124 is the most abundant miRNA in the adult brain and serves a tumor-suppressive role in diverse types of cancer, including those of the breast and prostate ([@b7-ol-0-0-7131],[@b8-ol-0-0-7131]). miR-124 is potentially involved in liver cancer: miR-124 suppresses aggressive hepatocellular carcinoma by repressing Rho-associated, coiled-coil containing protein kinase 2 and enhancer of zeste 2 polycomb repressive complex 2 subunit ([@b9-ol-0-0-7131]). miR-124 overexpression appears to repress the migration and invasion of intrahepatic cholangiocarcinoma cells *in vitro* ([@b10-ol-0-0-7131]). This evidence indicates that miR-124 may serve a complicated tumor-suppressive role in hepatoblastoma.; however, its underlying molecular mechanism remains elusive.

The activity of miRNAs is negatively associated with the expression of their target mRNAs ([@b11-ol-0-0-7131]--[@b13-ol-0-0-7131]). On this basis, miR-124 transfection has been used to identify its downregulated target mRNAs by microarray time-course experiments ([@b14-ol-0-0-7131]). These target genes may be implicated in various biological functions and signaling pathways, thereby contributing to the progression of hepatoblastoma. To further investigate the underlying mechanisms of miR-124 overexpression in hepatoblastoma, the present study applied a range of bioinformatics approaches to a microarray dataset (GSE6207). Differentially expressed genes (DEGs) between human hepatoblastoma HepG2 cells transfected with a miR-124 duplex or a negative control RNA duplex at different time points (4, 8, 16, 24, 32, 72 and 120 h) were screened, followed by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the screened DEGs. Changes in miR-124 activity over the time course were also analyzed. miR-124-target mRNA pairs were then selected to construct miR-124-target mRNA networks for each time point. Gene ontology (GO) function and KEGG pathway enrichment analysis were performed for the targets genes of miR-124. The present study therefore provides additional data concerning the molecular mechanisms of miR-124 in hepatoblastoma.

Materials and methods
=====================

### Microarray data and preprocessing

The present study used the GSE6207 microarray dataset, downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (GEO; <https://www.ncbi.nlm.nih.gov/geo/>) repository based on the Affymetrix Human Genome U133 Plus 2.0 Array platform ([@b14-ol-0-0-7131]). It included RNA samples extracted from HepG2 cells transfected with a miRNA-124 duplex or a negative control, with one sample for each time point (4, 8, 16, 24, 32, 72 and 120 h). The gene expression data were sequentially preprocessed with background correction, quantile normalization and probe summarization using robust multiarray analysis (RMA) of the affy package in R ([@b15-ol-0-0-7131]). The expression values of several probes that correspond to a certain gene were averaged, and the averaged expression value was defined as the expression value of the gene.

### DEG screening

DEGs at each time point were screened in the HepG2 cells transfected with the miRNA-124 duplex and those transfected with the negative control RNA duplex. As there was only one sample for each experimental condition at each time point, \|log~2~ fold change\| ≥0.58 was set as the strict cutoff ([@b16-ol-0-0-7131]). The expression values of DEGs at different time points were hierarchically clustered using Cluster software (version 3.0; <http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm>), which was originally developed by Michael Eisen while at Stanford University ([@b17-ol-0-0-7131]), and displayed in a heat map.

### KEGG pathway enrichment analysis

To unravel the pathways involving the DEGs at each time point, KEGG pathway enrichment analysis was performed for the DEGs using Database for Annotation, Visualization and Integration Discovery (DAVID), with P\<0.05 as the cutoff value ([@b18-ol-0-0-7131]).

### Inferred activity of miR-124

The regulatory activity of miRNAs is negatively associated with the expression of their target mRNAs, which could be measured by microarray. When the expression of the target mRNA is downregulated, the activity of the miRNAs is enhanced, and when the target mRNA expression is upregulated, the activity of the corresponding miRNA is inhibited ([@b12-ol-0-0-7131]). On this basis, the miR-124 activity at each time point in the study was inferred by combing microarray expression data with miRNA target predictions, as described in a previous study \[the number of permutations for binding vectors (k)=1,000\] ([@b12-ol-0-0-7131]).

### Construction of miRNA-target mRNA networks

The target mRNAs of miRNA-124 at each time point were predicted using five repositories: miRanda (<http://www.microrna.org/microrna/home.do>), MirTarget2 (<http://nar.oxfordjournals.org/cgi/content/abstract/34/5/1646>), PicTar (<http://pictar.mdc-berlin.de/>), PITA (<https://genie.weizmann.ac.il/pubs/mir07/mir07_data.html>) and TargetScan (<http://www.targetscan.org/vert_71/>) ([@b19-ol-0-0-7131]--[@b23-ol-0-0-7131]). These repositories provide information on the integration of miRNA target prediction with expression files. Only the miR-124-target mRNA pairs that were validated in at least three out of the five databases were selected and included in the miR-124-target gene network. Expression values of miRNA-124-target genes at different time points were hierarchically clustered using Cluster software. Furthermore, GO function ([@b24-ol-0-0-7131]) and KEGG pathway enrichment analysis were performed for functional annotation of the obtained target genes in the network, with P\<0.05 as the strict threshold.

Results
=======

### Screening of DEGs at different time points

DEGs in HepG2 cells transfected with the miRNA-124 duplex and negative control were screened at 4, 8, 16, 24, 32, 72 and 120 h. As shown in [Fig. 1](#f1-ol-0-0-7131){ref-type="fig"}, the total count of DEGs increased following transfection, reaching its peak at 72 h and then decreasing. Of the DEGs, there were more downregulated genes than upregulated genes at 4, 8, 16, 24, 32 and 72 h after transfection. The exception was 120 h, when there were more upregulated genes than downregulated genes. The expression data of all DEGs at seven time points is displayed in [Fig. 2](#f2-ol-0-0-7131){ref-type="fig"}.

### KEGG pathway enrichment analysis for DEGs

Pathways significantly enriched for upregulated DEGs at different time points are shown in [Table I](#tI-ol-0-0-7131){ref-type="table"}. No significant pathways were detected at 4, 8 or 16 h; genes involved in the tumor protein p53 signaling and retinol metabolism pathways were significantly associated with upregulated genes at 24 h after transfection. Expression of genes involved in the p53, systemic lupus erythematosus and mitogen-activated protein kinase (MAPK) signaling pathways were significantly upregulated at 32 h; those involved in axon guidance and adherens junction pathways were significantly upregulated at 72 h; those involved in glycerolipid metabolism and p53 signaling pathways were significantly upregulated at 120 h. With respect to downregulated DEGs ([Table II](#tII-ol-0-0-7131){ref-type="table"}), no significant pathway was detected at 4 or 16 h; those involved in the ribosome pathway (hsa03010: ribosome) were significantly downregulated at 8 h; those involved in small cell lung cancer, sphingolipid metabolism and the cell cycle were significantly downregulated at 24 h; those involved in small cell lung cancer, the cell cycle and pathways in cancer were significantly downregulated at 32 h; those involved in the cell cycle and DNA replication pathways were significantly associated with downregulated genes at 72 h; and those involved in the complement and coagulation cascades, cell cycle, and valine, leucine and isoleucine degradation pathways were significantly downregulated at 120 h.

### Activity changes of miRNA-124

The changes in activity of miR-124 following transfection are shown in [Fig. 3](#f3-ol-0-0-7131){ref-type="fig"}. The activity of miR-124 varied with time after transfection: It was highest at 4 h after transfection. The activity of miR-124 was higher in the experimental group than that in the control group at 4, 8, 16 and 24 h after transfection. By contrast, the experimental group exhibited decreased miR-124 activity compared with that of the control group at 72 h after transfection. Notably, at 32 h, the activity of miR-124 in the experimental group was similar to that in the control group.

### miR-124-target gene network analysis

The target mRNAs of miRNA-124 at each time point were predicted based on the aforementioned five repositories (miRanda, MirTarget2, PicTar, PITA and TargetScan). To investigate the association between miR-124 and its target genes, the miR-124-target gene pairs validated in at least three out of these five databases were used to construct miR-124-target gene networks for each time point. The expression values of all the predicted target genes at different time points are shown in a heat map ([Fig. 4](#f4-ol-0-0-7131){ref-type="fig"}).

The miR-124-target gene networks are shown in [Fig. 5](#f5-ol-0-0-7131){ref-type="fig"}. At 4 and 8 h after transfection, all miR-124-target genes were downregulated, indicating high miR-124 activity. At 16, 24 and 32 h, a small proportion of the target genes were upregulated, whereas the majority of the target genes were downregulated. By contrast, more upregulated genes were observed at 72 and 120 h when compared to that at 16, 24 and 32 h, indicating a reduction in miR-124 activity.

### Functional annotation for target genes of miR-124

GO functional enrichment analysis was performed for miR-124-target genes at different time points. No significant GO term was enriched at 4 or 8 h. As shown in [Table III](#tIII-ol-0-0-7131){ref-type="table"}, Ras protein signal transduction was a significant GO term at 16 h and was enriched with syndecan binding protein (*SDCBP*), Ras homolog family member G (*RHOG*) and Rho GDP dissociation inhibitor-α (*ARHGDIA*). At 24 h, small GTPase-mediated signal transduction and Ras protein signal transduction were primary GO terms, and the two were significantly enriched with *SDCBP, RHOG* and *ARHGDIA*, Rho-guanine nucleotide exchange factor 3 (*ARHGEF3*), GTPase activating protein (SH3 domain) binding protein 1 (*G3BP1*) and V-Ral simian leukemia viral oncogene homolog A (*RALA*). Similarly, at 32 h, the two GO terms were also enriched with the above six genes. Cell cycle and intracellular transport were significant GO terms at 72 h. A total of 44 genes were significantly associated with the cell cycle, such as kinesin family member 23 (*KIF23*), *KIF15*, cell division cycle 27 (*CDC27*) and *CDC25A*. A total of 38 genes were significantly involved in intracellular transport, such as adaptor-related protein complex 1, µ-1 subunit (*AP1M1*), adaptor-related protein complex 1, µ-2 subunit (*AP1M2*), KDEL endoplasmic reticulum protein retention receptor 1 (*KDELR1*) and *KDELR2*. At 120 h, cell motion was significantly associated with 17 genes, such as talin 1 *(TLN1)* and protein tyrosine phosphatase, receptor type, M (*PTPRM*), while intracellular transport was significantly associated with 18 genes, such as karyopherin-α *(KPNA)5, KPNA3* and *KPNA1*.

The potential signaling pathways and target genes that may be involved in these signaling pathways were also analyzed ([Table IV](#tIV-ol-0-0-7131){ref-type="table"}). No significant pathways were enriched with target genes at 4, 8 or 16 h. Regulation of the actin cytoskeleton pathway was a significant pathway at 24 h, and was enriched with several target genes, including cofilin 2 (*CFL2*) and WAS protein family, member 1 (*WASF1*). The target genes were predominantly associated with small cell lung cancer and ether lipid metabolism pathways at 32 h. At 72 h, the D-glutamine and D-glutamate metabolism pathway was significantly enriched with glutamate dehydrogenase 1 (*GLUD1*) and *GLUD2*. At 120 h, axon guidance, adherens junction and the transforming growth factor β signaling pathway were enriched. The axon guidance pathway was significant at 72 and 120 h, and was enriched with a number of target genes, such as neuropilin 1 (*NRP1*), MET proto-oncogene, receptor tyrosine kinase (*MET*) and semaphorin 7A, GPI membrane anchor (*SEMA7A*).

Discussion
==========

miRNAs participate in a variety of cell activities via suppression of the expression of their target genes ([@b25-ol-0-0-7131]). The molecular mechanism by which miR-124 results in suppression of hepatoblastoma is not entirely clear. The present study revealed that the total number of DEGs in hepatoblastoma cells increased with time following miR-124 transfection, reached a peak at 72 h and then decreased, compared with the findings in cells treated with a negative control. miR-124 overexpression led to more downregulated genes than upregulated genes at 4, 8, 16, 24, 32 and 72 h, which was partly consistent with the fact that miR-124 inhibits the expression of its target genes ([@b26-ol-0-0-7131]). However, a proportion of DEGs were upregulated following miR-124 transfection. An explanation for this observation is that the upregulated DEGs may be the result of downregulation of DEGs by miR-124 overexpression. miRNAs may regulate the expression of other miRNAs ([@b12-ol-0-0-7131],[@b27-ol-0-0-7131]), which could therefore strengthen or inhibit the activity of other endogenous miRNAs, thus contributing to differential expression of their target genes. These inhibited miRNAs may cause upregulation of their target genes.

Small GTPases are intracellular G proteins and hydrolase enzymes that hydrolyze guanosine triphosphate. They serve a key role in diverse cell activities, including cell growth, differentiation, movement and lipid vesicle transport ([@b28-ol-0-0-7131],[@b29-ol-0-0-7131]). Ras protein family members belong to the small GTPase family. Ras is an intracellular anti-apoptotic protein that is closely associated with the phosphoinositide 3-kinase/AKT and MAPK signaling pathways, regulating various activities, including cell apoptosis and growth ([@b30-ol-0-0-7131],[@b31-ol-0-0-7131]). Several lines of evidence have suggested that small GTPases have a regulatory role in hepatoblastoma ([@b32-ol-0-0-7131],[@b33-ol-0-0-7131]). Consistent with this, the present study revealed that small GTPase-mediated signal transduction and Ras protein signal transduction were significant GO categories, enriched with *SDCBP, RHOG* and *ARHGDIA* in hepatoblastoma at 24 and 32 h. *SDCBP* encodes syntenin-1, which is a tandem PDZ domain-containing protein involved in trafficking, signaling and cancer metastasis ([@b34-ol-0-0-7131]). Syntenin-1 is implicated in regulating colon cancer cell migration ([@b35-ol-0-0-7131]). However, the role of *SDCBP* in hepatoblastoma has not been previously reported. *RHOG* encodes the Ras homology growth-related (RhoG) protein, which is a small GTP-binding protein and a member of the Rac subgroup of the Rho family ([@b36-ol-0-0-7131]). The Rac signaling pathways serve an essential role in the motility of hepatocellular carcinoma cells ([@b37-ol-0-0-7131]). *ARHGDIA* encodes Rho GDP-dissociation inhibitor 1 protein, which participates in regulating Rho activity. The absence of *ARHGDIA* has been reported to enhance the invasion and metastasis of hepatocellular carcinoma cells ([@b37-ol-0-0-7131]). However, the role of these genes in hepatoblastoma has not been reported thus far. Thus, the present study speculated that miR-124 overexpression may lead to the inhibition of small GTPase-mediated signal transduction and Ras protein signal transduction by regulating *SDCBP, RHOG* and *ARHGDIA*, thereby repressing hepatoblastoma development.

The present study unraveled that regulation of the actin cytoskeleton pathway was significantly enriched with several target genes such as *CFL2* at 24 h after transfection. Regulation of the actin cytoskeleton pathway is involved in cancer cell migration, tumor invasion and metastasis ([@b38-ol-0-0-7131]). CFL2 is an intracellular actin-modulating protein that regulates actin-filament dynamics ([@b39-ol-0-0-7131]); it indicates that miR-124 overexpression may inhibit cancer cell migration, tumor invasion and metastasis by regulating actin cytoskeleton pathway genes such as *CFL2*. Furthermore, the present study revealed that the D-glutamine and D-glutamate metabolism pathways were enriched (*GLUD1* and *GLUD2*) at 72 h. The D-glutamine and D-glutamate metabolic pathways are critical components of protein synthesis and cellular energy production ([@b40-ol-0-0-7131],[@b41-ol-0-0-7131]). *GLUD1* and *GLUD2* are two mitochondrial matrix enzymes that serve a key role in glutamate metabolism and energy homeostasis ([@b42-ol-0-0-7131]). The findings of the present study revealed that miR-124 transfection may affect glutamate metabolism and energy homeostasis.

Notably, the expression of *NRP1, SEMA7A* and *MET*, which are involved in the axon guidance signaling pathway, was significantly increased at 72 and 120 h. An aberrant axon guidance pathway is involved in pancreatic carcinogenesis ([@b43-ol-0-0-7131]). Nevertheless, the role of the axon guidance pathway in hepatoblastoma has not been clearly characterized. Neuropilin-1, encoded by *NRP1*, is a co-receptor member for members of the semaphorin family, and is involved in several cellular processes, including angiogenesis and cell survival ([@b44-ol-0-0-7131]). A previous study revealed that the expression of *NRP1* is higher in HepG2 cell lines than that in a human normal hepatic cell line, indicating the effect of *NRP1* on hepatoblastoma ([@b45-ol-0-0-7131]). SEMA7A, which is encoded by *SEMA7A*, is a membrane-bound semaphorin and promotes axon outgrowth ([@b46-ol-0-0-7131]). *MET* encodes hepatocyte growth factor receptor (HGFR), which has tyrosine kinase activity and binds to HGF. It has been reported that invasion of hepatocellular carcinoma cells is dependent on HGF ([@b47-ol-0-0-7131]). Furthermore MET/HGF inhibitors have been increasingly recognized as anticancer therapies for various types of cancer, including hepatoma ([@b48-ol-0-0-7131]). These observations indicate that axon guidance pathway genes may be abnormally regulated due to miR-124 overexpression, thereby suppressing hepatoblastoma cell growth and invasion. The present study indicates the presence of an as-yet-undescribed role of the axon guidance pathway in hepatoblastoma.

The current study demonstrated that miR-124 overexpression may perturb small GTPase-mediated signal transduction and Ras protein signal transduction, and abnormally affect the regulation of the actin cytoskeleton, D-glutamine and D-glutamate metabolic and axon guidance pathways in hepatoblastoma. *SDCBP, RHOG, ARHGDIA, NRP1, SEMA7A* and *MET* may be promising molecular targets for therapies against hepatoblastoma. These pathways are not specific to hepatoblastoma, but may also be involved in other types of cancer. These findings provide useful information concerning the molecular mechanisms that underlie the tumor-suppressive role of miR-124 in hepatoblastoma. Further experimental studies are warranted to validate the findings of the present study.
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###### 

KEGG pathways enriched with upregulated differentially expressed genes at different time points.

  Time after transfection, h   KEGG pathway identity                                                   Enriched genes, n   P-value
  ---------------------------- ----------------------------------------------------------------------- ------------------- -------------
  24                           hsa04115:p53 signaling pathway                                            5                 1.00×10^−3^
                               hsa00830:Retinol metabolism                                               3                 5.00×10^−2^
  32                           hsa04115:p53 signaling pathway                                            5                 1.02×10^−2^
                               hsa05322:Systemic lupus erythematosus                                     5                 3.53×10^−2^
                               hsa04010:MAPK signaling pathway                                           8                 4.90×10^−2^
  72                           hsa04360:Axon guidance                                                  17                  4.41×10^−3^
                               hsa04520:Adherens junction                                              12                  6.03×10^−3^
                               hsa04144:Endocytosis                                                    20                  1.44×10^−2^
                               hsa00051:Fructose and mannose metabolism                                  7                 1.48×10^−2^
                               hsa05130:Pathogenic *Escherichia coli* infection                          9                 2.00×10^−2^
                               hsa04115:p53 signaling pathway                                          10                  2.00×10^−2^
                               hsa05410:Hypertrophic cardiomyopathy (HCM)                              11                  3.09×10^−2^
                               hsa05412:Arrhythmogenic right ventricular cardiomyopathy                10                  3.81×10^−2^
                               hsa00983:Drug metabolism                                                  7                 4.26×10^−2^
                               hsa05414:Dilated cardiomyopathy                                         11                  4.93×10^−2^
  120                          hsa00561:Glycerolipid metabolism                                          8                 4.35×10^−3^
                               hsa04115:p53 signaling pathway                                            9                 1.30×10^−2^
                               hsa00140:Steroid hormone biosynthesis                                     7                 1.89×10^−2^
                               hsa04070:Phosphatidylinositol signaling system                            9                 2.09×10^−2^
                               hsa05120:Epithelial cell signaling in *Helicobacter pylori* infection     8                 3.77×10^−2^
                               hsa00564:Glycerophospholipid metabolism                                   8                 3.77×10^−2^
                               hsa05211:Renal cell carcinoma                                             8                 4.32×10^−2^
                               hsa04650:Natural killer cell-mediated cytotoxicity                      12                  4.49×10^−2^
                               hsa00983:Drug metabolism                                                  6                 4.80×10^−2^

KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; hsa, *Homo sapiens*.

###### 

KEGG pathways enriched with downregulated differentially expressed genes at different time points.

  Time after transfection, h   Term                                                  Enriched genes, n   P-value
  ---------------------------- ----------------------------------------------------- ------------------- --------------
  8                            hsa03010:Ribosome                                       3                 2.30×10^−2^
  24                           hsa05222:Small cell lung cancer                         9                 7.02×10^−4^
                               hsa00600:Sphingolipid metabolism                        5                 1.25×10^−2^
                               hsa04110:Cell cycle                                     8                 2.65×10^−2^
                               hsa00565:Ether lipid metabolism                         4                 4.75×10^−2^
  32                           hsa05222:Small cell lung cancer                       11                  6.88×10^−5^
                               hsa04110:Cell cycle                                   10                  5.95×10^−3^
                               hsa05212:Pancreatic cancer                              7                 1.21×10^−2^
                               hsa05200:Pathways in cancer                           16                  2.79×10^−2^
                               hsa00480:Glutathione metabolism                         5                 4.37×10^−2^
  72                           hsa04110:Cell cycle                                   46                  7.63×10^−20^
                               hsa03030:DNA replication                              20                  1.43×10^−12^
                               hsa04914:Progesterone-mediated oocyte maturation      19                  8.17×10^−5^
                               hsa03040:Spliceosome                                  24                  8.48×10^−5^
                               hsa00240:Pyrimidine metabolism                        20                  9.97×10^−5^
                               hsa03430:Mismatch repair                                9                 2.18×10^−4^
  120                          hsa04610:Complement and coagulation cascades          16                  1.39×10^−9^
                               hsa04110:Cell cycle                                   11                  4.75×10^−3^
                               hsa00280:Valine, leucine and isoleucine degradation     6                 1.05×10^−2^
                               hsa00260:Glycine, serine and threonine metabolism       5                 1.41×10^−2^
                               hsa05020:Prion diseases                                 5                 2.13×10^−2^
                               hsa00910:Nitrogen metabolism                            4                 3.20×10^−2^

KEGG, Kyoto Encyclopedia of Genes and Genomes; hsa, *Homo sapiens*.

###### 

GO terms enriched with target genes of microRNA-124 at different time points.

  Time after transfection, h   Term                                                    Enriched genes, n   P-value       Genes
  ---------------------------- ------------------------------------------------------- ------------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  16                           GO:0007265\~Ras protein signal transduction               3                 4.38×10^−2^   *SDCBP, RHOG, ARHGDIA*
  24                           GO:0007264\~small GTPase mediated-signal transduction   10                  1.47×10^−4^   *ARHGEF3, RAP2C, G3BP1, RALA, SDCBP, RAB6A, ARL8B, IQGAP1, RHOG, ARHGDIA*
                               GO:0007265\~Ras protein signal transduction               6                 5.71×10^−4^   *ARHGEF3, G3BP1, RALA, SDCBP, RHOG, ARHGDIA*
                               GO:0046907\~intracellular transport                     11                  9.37×10^−3^   *SLC25A20, SLC25A14, NRBP1, SCAMP2, TOM1L1, IPO4, SDCBP, SEC13, SLC25A1, ARFIP1, YWHAE*
                               GO:0006928\~cell motion                                   9                 1.13×10^−2^   *ENPP2, WASF1, KATNA1, SDCBP, LAMC1, PPAP2B, ITGB1, YWHAE, ARHGDIA*
                               GO:0015031\~protein transport                           11                  2.41×10^−2^   *SDAD1, SCAMP2, TOM1L1, SEH1L, IPO4, SDCBP, SEC13, SNX4, RAB6A, ARFIP1, YWHAE*
  32                           GO:0007264\~small GTPase mediated-signal transduction   11                  1.61×10^−4^   *ARHGEF3, RAP2C, G3BP1, RALA, SDCBP, RAB6A, ARL8B, IQGAP1, RHOG, ARHGDIA, RGL1*
                               GO:0007265\~Ras protein signal transduction               6                 1.52×10^−3^   *ARHGEF3, G3BP1, RALA, SDCBP, RHOG, ARHGDIA*
                               GO:0006928\~cell motion                                 11                  4.64×10^−3^   *TLN1, CCR6, ENPP2, WASF1, KATNA1, SDCBP, LAMC1, SRF, PPAP2B, ITGB1, ARHGDIA*
                               GO:0046907\~intracellular transport                     13                  6.11×10^−3^   *SCAMP2, NRBP1, AP1M2, ARFIP1, FLNA, SLC25A20, SLC25A14, KIF1B, IPO4, SDCBP, SEC13, TRAPPC4, SLC25A1*
                               GO:0051329\~interphase of mitotic cell cycle              5                 9.28×10^−3^   *PPM1D, KATNA1, CDK4, ITGB1, CDC25A*
  72                           GO:0007049\~cell cycle                                  44                  3.69×10^−7^   *KIF23, CKS1B, E2F3, TUBB2B, CDC16, ITGB1, SESN1, CTNNB1, CCNE2, APP, NDE1, RAD21, DUSP13, SEH1L, CENPA, KATNA1, RB1CC1, TFDP2, VPS4A, PPP3CA, HELLS, CSRP2BP, NASP, KIF15, SUV39H1, SMAD3, MND1, ILF3, GAS2, MCM2, CDK4, CDC27, CDC25A, SMC4, MCM6, PPM1G, PA2G4, PPM1D, FANCD2, PLK1, GAS2L1, SETD8, SIAH2, ACVR1*
                               GO:0046907\~intracellular transport                     38                  1.79×10^−6^   *NUP98, AP1M1, AP1M2, SEC24A, NRBP1, EIF5A, BCL2L1, KLC2, LMAN1, SLC25A20, AP1S1, APP, AP2B1, NDE1, CSE1L, ZFYVE9, VPS4A, SLC25A1, PPP3CA, SAR1B, KDELR1, XPOT, GABARAPL2, KDELR2, SCAMP2, VPS41, ARFIP1, SLC25A12, SLC25A14, TOM1L1, IPO4, TRAPPC4, SEC13, SDCBP, KPNA5, KPNA3, TRAPPC1, SSR2*
                               GO:0022402\~cell cycle process                          33                  8.30×10^−6^   *KIF23, TUBB2B, CDC16, ITGB1, SESN1, CTNNB1, APP, NDE1, RAD21, DUSP13, SEH1L, CENPA, KATNA1, PPP3CA, HELLS, CSRP2BP, KIF15, SMAD3, MND1, ILF3, GAS2, CDK4, CDC27, CDC25A, SMC4, PPM1G, PA2G4, PPM1D, FANCD2, PLK1, GAS2L1, SETD8, ACVR1*
                               GO:0048193\~Golgi vesicle transport                     13                  8.58×10^−5^   *GABARAPL2, AP1M1, SCAMP2, NRBP1, SEC24A, AP1M2, VPS41, LMAN1, AP1S1, SEC13, TRAPPC4, TRAPPC1, SAR1B*
                               GO:0070727\~cellular macromolecule localization         24                  2.12×10^−4^   *KDELR2, AP1M1, NUP98, SEC24A, AP1M2, EIF5A, VPS41, ARFIP1, CASC3, CTNNB1, AP1S1, AP2B1, CSE1L, TOM1L1, IPO4, ZFYVE9, SEC13, SDCBP, KPNA5, PPP3CA, SAR1B, KPNA3, KDELR1, SSR2*
  120                          GO:0006928\~cell motion                                 17                  1.86×10^−4^   *TLN1, NRP1, PTPRM, ENPP2, WASF1, MET, L1CAM, NRCAM, APP, CCR6, TNS1, KATNA1, SDCBP, NOS3, PAFAH1B1, RELN, ACVR1*
                               GO:0046907\~intracellular transport                     18                  2.27×10^−3^   *AP1M1, SEC24A, NRBP1, YWHAB, VPS41, LMAN1, SLC25A20, APP, SLC25A14, VPS4A, SDCBP, SEC13, SLC25A1, PAFAH1B1, KPNA5, KPNA3, KPNA1, SEC61A2*
                               GO:0032355\~response to estradiol stimulus                5                 3.94×10^−3^   *BMP4, SOCS2, ENO2, NOS3, IGFBP2*
                               GO:0016477\~cell migration                              10                  6.03×10^−3^   *NRCAM, TNS1, NRP1, KATNA1, MET, SDCBP, NOS3, PAFAH1B1, RELN, ACVR1*
                               GO:0006796\~phosphate metabolic process                 22                  6.12×10^−3^   *ATP6V0E1, NRBP1, PTPRM, PTPN3, SLC20A1, ENPP2, ERBB3, SMAD7, TBK1, STK36, MET, DUSP10, OXSR1, PPM1B, CDK4, MAST3, PPM1D, APP, RELN, PAK1, ATP6V0D1, ACVR1*

GO, gene ontology.

###### 

Kyoto Encyclopedia of Genes and Genomes pathways enriched with target genes of microRNA-124 at different time points.

  Time after transfection, h   Term                                              Enriched genes, n   P-value       Genes
  ---------------------------- ------------------------------------------------- ------------------- ------------- ------------------------------------------------------------------------------------------------------------
  24                           hsa04810:Regulation of actin cytoskeleton           5                 4.87×10^−2^   *CFL2, WASF1, ITGB1, IQGAP1, NCKAP1*
  32                           hsa05222:Small cell lung cancer                     4                 3.14×10^−2^   *E2F3, LAMC1, CDK4, ITGB1*
                               hsa00565:Ether lipid metabolism                     3                 3.34×10^−2^   *ENPP2, PPAP2B, AGPAT1*
  72                           hsa04360:Axon guidance                            15                  6.34×10^−6^   *NRP1, MET, DPYSL2, ITGB1, EPHA2, SEMA6A, ROBO1, SEMA7A, SEMA3F, CFL2, NFAT5, PAK1, PPP3CA, NFATC3, RASA1*
                               hsa04110:Cell cycle                               14                  2.20×10^−5^   *E2F3, E2F5, SMAD3, MCM2, CDC16, CDK4, CDC27, CDC25A, MCM5, MCM6, CCNE2, RAD21, PLK1, TFDP2*
                               hsa05212:Pancreatic cancer                          9                 5.74×10^−4^   *E2F3, RALBP1, RELA, ARAF, PIK3CD, SMAD3, RALA, BCL2L1, CDK4*
                               hsa05222:Small cell lung cancer                     9                 1.60×10^−3^   *CCNE2, CKS1B, E2F3, RELA, PIK3CD, LAMC1, BCL2L1, CDK4, ITGB1*
                               hsa00471:D-Glutamine and D-glutamate metabolism     3                 4.05×10^−3^   *GLS2, GLUD2, GLUD1*
  120                          hsa04360:Axon guidance                              7                 1.29×10^−2^   *NRP1, CFL2, SEMA7A, MET, NFAT5, L1CAM, PAK1*
                               hsa04520:Adherens junction                          5                 2.86×10^−2^   *PTPRM, WASF1, MET, PVRL2, IQGAP1*
                               hsa04350:TGF-β signaling pathway                    5                 4.21×10^−2^   *BMP4, ID2, SP1, SMAD7, ACVR1*

hsa, *Homo sapiens*; TGF, transforming growth factor.

[^1]: Contributed equally
